Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis
暂无分享,去创建一个
[1] S. Reingold,et al. Defining the clinical course of multiple sclerosis , 1996, Neurology.
[2] C. Granger,et al. Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.
[3] Christian Confavreux,et al. Recommendations from the national multiple sclerosis society clinical outcomes assessment task force , 1997, Annals of neurology.
[4] Karl E. Peace,et al. Biopharmaceutical Statistics in Drug Development , 1989 .
[5] R. Rudick,et al. Multiple sclerosis : advances in clinical trial design, treatment, and future perspectives , 1996 .
[6] J. Petkau,et al. Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis , 1997, Multiple sclerosis.
[7] Moses Rodriguez,et al. Distinct Patterns of Multiple Sclerosis Pathology Indicates Heterogeneity in Pathogenesis , 1996, Brain pathology.
[8] D. Paty,et al. Scales for rating impairment in multiple sclerosis , 1988, Neurology.
[9] D. Silberberg,et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.
[10] Interferon beta-1b in secondary progressive multiple sclerosis--outline of the clinical trial. , 1995, Multiple sclerosis.
[11] J. Noseworthy,et al. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial , 1990, Neurology.
[12] M. Åsberg,et al. A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.
[13] D. Wolinsky,et al. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: A randomized, double‐blinded, placebo‐controlled clinical trial , 1990 .
[14] D. Bates,et al. The multiple sclerosis PRISMS study: Prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis , 1997 .
[15] J. Baskerville,et al. Meta-analysis of the placebo-treated groups in clinical trials of progressive MS , 1996, Neurology.
[16] J. Petkau. Statistical and Design Considerations for Multiple Sclerosis Clinical Trials , 1996 .
[17] R. Loos,et al. Utilisation and cost of professional care and assistance according to disability of patients with multiple sclerosis in Flanders (Belgium) , 1998, Journal of neurology, neurosurgery, and psychiatry.
[18] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.